Seattle Genetics Inc. (Nasdaq: SGEN) reported upbeat results from a Phase 3 ECHELON-1 clinical trial of adcetris to treat classical Hodgkin lymphoma but the stock price plunged $5.19 to close at $56.55.
Seattle Genetics tumbles despite upbeat results
June 26, 2017 at 17:31 PM EDT
